Eupraxia Pharmaceuticals Inc
Officers & Directors
James A. Helliwell has served as Chief Executive Officer and Director of Eupraxia Pharmaceuticals Inc. since July 23, 2012. Amanda Malone has been the Chief Scientific Officer and Chief Operating Officer since September 2012. Alex Rothwell was appointed Chief Financial Officer in February 2025. Paul Brennan has held the position of Chief Business Officer since December 2022. Mark Kowalski has served as Chief Medical Officer since May 2023.
Simon Pimstone is Chairman of the Board and Director, appointed director on January 14, 2013, and chairman on January 24, 2013. He is also founder and CEO of XYON Health Inc. since January 2019 and held various leadership roles at Xenon Pharmaceuticals, Inc. from 2003 to 2024. Richard M. Glickman, appointed director on March 9, 2021, serves as Director and is Chairman of the Board of enGene Inc. since October 2011 and ESSA Pharma Inc. since October 2010. He has held executive roles at Aurinia Pharmaceuticals Inc. and Lumira Ventures.
Paul Geyer, appointed director on January 14, 2013, is a Director and CEO of Geyer Family Office and Chief Investment Officer of Nimbus Synergies since 2025. He was CEO of Discovery Parks and Nimbus Synergies from May 2017 to 2025. John Montalbano, appointed director on January 14, 2013, is a Director and serves on the boards of AbCellera Biologics Inc., XYON Health Inc., Canada Pension Plan Investment Board, Aritzia Inc., and Manulife. Michael Wilmink, appointed director on January 14, 2013, is a Director and Orthopaedic Surgeon, partner in the OrthoArizona practice since 2002. Joseph Freedman, appointed director on October 31, 2024, is a Director and Chairman of the Board at the Centre for Aging and Brain Health Innovation since 2021, and serves as director at Bridgemarq Real Estate Services and Total Containment Inc.
News about Eupraxia Pharmaceuticals Inc Key Personnel |
VICTORIA, BC, April 11, 2024 - Eupraxia Pharmaceuticals Inc. (Eupraxia or the Company) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs, has recently announced its participation in the Osteoarthritis Research Society International World Congress 2024.
The Osteoarthritis Research Society International World Congress is a prominent gathering of experts, researchers, and academic professionals in the field of osteoarthritis. The event provides a platform for the exchange of knowledge, latest research findings, and new advancements in the field. Eupraxia Pha...
|
|
